# Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer

> **NCT00574769** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Southern California** · enrollment: 27 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** RAD001, Docetaxel, Bevacizumab

## Key facts

- **NCT ID:** NCT00574769
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-17
- **Primary completion:** 2016-02-17
- **Final completion:** 2017-02-17
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2017-04-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00574769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00574769, "Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00574769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*